Inhibikase Therapeutics I...

NASDAQ: IKT · Real-Time Price · USD
1.73
0.02 (1.17%)
At close: Aug 15, 2025, 12:37 PM

Inhibikase Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a 260.5K 123.44K 3.1M
Cost of Revenue
n/a 13.62M 6.72K 11.36M
Gross Profit
n/a -13.36M 116.72K -8.26M
Operating Income
-28.59M -20.09M -18.13M -14.77M
Interest Income
1.07M 1.06M 74.45K 19.92K
Pretax Income
-27.52M -19.03M -18.05M -14.79M
Net Income
-27.52M -19.03M -17.91M -14.81M
Selling & General & Admin
11.38M 6.73M 6.22M 6.51M
Research & Development
17.21M 13.62M 12.03M 11.36M
Other Expenses
n/a -13.62M -123.44K -3.1M
Operating Expenses
28.56M 6.73M 18.13M 14.77M
Interest Expense
n/a n/a 74.45K 19.92K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
28.59M 20.35M 18.13M 14.77M
Income Tax Expense
n/a n/a -148.91K 19.92K
Shares Outstanding (Basic)
23.71M 5.33M 4.2M 3.03M
Shares Outstanding (Diluted)
23.71M 5.33M 4.2M 3.03M
EPS (Basic)
-1.16 -3.57 -4.26 -4.88
EPS (Diluted)
-1.16 -3.57 -4.26 -4.88
EBITDA
-27.49M -19.91M -18.12M -14.77M
EBIT
-27.52M -20.09M -18.13M -14.77M
Depreciation & Amortization
26.27K 177.4K 6.72K 14.77M